In vivo antitumor effect of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma

References

• Abdollahi A, Lipson KE, Sckell A, et al. (2003). Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 63:8890–8.
   PubMed Web of Science ®Google Scholar
• Al-Qadi S, Grenha A, Carrión-Recio D, et al. (2012). Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations. J Control Release 157:383–90.
   PubMed Web of Science ®Google Scholar
• Amidi M, Mastrobattista E, Jiskoot W, et al. (2010). Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev 62:59–82.
   PubMed Web of Science ®Google Scholar
• Azzoli CG, Temin S, Giaccone G. (2012). 2011 Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Oncol Pract 8:63–6.
   PubMedGoogle Scholar
• Cairns R, Papandreou I, Denko N. (2006). Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 4:61–70.
   PubMed Web of Science ®Google Scholar
• Calvo P, Remuñan-López C, Vila-Jato JL, Alonso MJ. (1997). Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res 14:1431–6.
   PubMed Web of Science ®Google Scholar
• Chauhan VP, Stylianopoulos T, Boucher Y, et al. (2011). Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2:281–98.
   PubMed Web of Science ®Google Scholar
• Chen W, Hu S. (2011). Suitable carriers for encapsulation and distribution of endostar: comparison of endostar-loaded particulate carriers. Int J Nanomedicine 6:1535–41.
   PubMed Web of Science ®Google Scholar
• Ding RL, Xie F, Hu Y, et al. (2017). Preparation of endostatin-loaded chitosan nanoparticles and evaluation of the antitumor effect of such nanoparticles on the Lewis lung cancer model. Drug Deliv 24:300–8.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Kerbel RS. (2005). Angiogenesis as a therapeutic target. Nature 438:967–74.
   PubMed Web of Science ®Google Scholar
• Fukumura D, Jain RK. (2007). Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 74:72–84.
   PubMed Web of Science ®Google Scholar
• Gao J, Knutsen A, Arbman G, et al. (2009). Clinical and biological significance of angiogenesis and lymphangiogenesis in colorectal cancer. Dig Liver Dis 41:116–22.
   PubMedGoogle Scholar
• Gillies RJ, Robey I, Gatenby RA. (2008). Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49:24S–42s.
   PubMed Web of Science ®Google Scholar
• Han B, Xiu Q, Wang H, et al. (2011). A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol 6:1104–9.
   PubMed Web of Science ®Google Scholar
• Jain RK, Stylianopoulos T. (2010). Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7:653–64.
   PubMed Web of Science ®Google Scholar
• Jia M, Li Y, Yang X, et al. (2014). Development of both methotrexate and mitomycin C loaded PEGylated chitosan nanoparticles for targeted drug codelivery and synergistic anticancer effect. ACS Appl Mater Interfaces 6:11413–23.
   PubMed Web of Science ®Google Scholar
• Jiang J, Liu Y, Wu C, et al. (2017). Development of drug-loaded chitosan hollow nanoparticles for delivery of paclitaxel to human lung cancer A549 cells. Drug Dev Ind Pharm 43:1304–13.
   PubMed Web of Science ®Google Scholar
• Kim YM, Hwang S, Kim Y-M, et al. (2002). Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 277:27872–9.
   PubMed Web of Science ®Google Scholar
• Klose R, Krzywinska E, Castells M, et al. (2016). Targeting VEGF-A in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia. Nat Commun 7:12528.
   PubMed Web of Science ®Google Scholar
• Lee KY, Ha WS, Park WH. (1995). Blood compatibility and biodegradability of partially N-acylated chitosan derivatives. Biomaterials 16:1211–16.
   PubMed Web of Science ®Google Scholar
• Li T, Kung H-J, Mack PC, et al. (2013). Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 31:1039–49.
   PubMed Web of Science ®Google Scholar
• Ling Y, Yang Y, Lu N, et al. (2007). Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 361:79–84.
   PubMed Web of Science ®Google Scholar
• Mukherjee B, Santra K, Pattnaik G, Ghosh S. (2008). Preparation, characterization and in-vitro evaluation of sustained release protein-loaded nanoparticles based on biodegradable polymers. Int J Nanomed 3:487–96.
   PubMed Web of Science ®Google Scholar
• Nasti A, Zaki NM, de Leonardis P, et al. (2009). Chitosan/TPP and chitosan/TPP-hyaluronic acid nanoparticles: systematic optimisation of the preparative process and preliminary biological evaluation. Pharm Res 26:1918–30.
   PubMed Web of Science ®Google Scholar
• O'Reilly MS, Boehm T, Shing Y, et al. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–85.
   PubMed Web of Science ®Google Scholar
• Rampino A, Borgogna M, Blasi P, et al. (2013). Chitosan nanoparticles: preparation, size evolution and stability. Int J Pharm 455:219–28.
   PubMed Web of Science ®Google Scholar
• Rong B, Shuanying Y, Wei L, et al. (2012). Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol 10:170.
   PubMed Web of Science ®Google Scholar
• Shi S, Chen L, Huang G. (2013). Antiangiogenic therapy improves the antitumor effect of adoptive cell immunotherapy by normalizing tumor vasculature. Med Oncol 30:698.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. (2017). Cancer statistics, 2017. CA Cancer J Clin 67:7–30.
   PubMed Web of Science ®Google Scholar
• Singh R, Lillard JW Jr. (2009). Nanoparticle-based targeted drug delivery. Exp Mol Pathol 86:215–23.
   PubMed Web of Science ®Google Scholar
• Sun XJ, Deng Q-H, Yu X-M, et al. (2016). A phase II study of endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer. BMC Cancer 16:266.
   PubMed Web of Science ®Google Scholar
• Swierczewska M, Han HS, Kim K, et al. (2016). Polysaccharide-based nanoparticles for theranostic nanomedicine. Adv Drug Deliv Rev 99:70–84.
   PubMed Web of Science ®Google Scholar
• Takahashi O, Komaki R, Smith PD, et al. (2012). Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clin Cancer Res 18:1641–54.
   PubMed Web of Science ®Google Scholar
• Tentler JJ, Bradshaw-Pierce EL, Serkova NJ, et al. (2010). Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clin Cancer Res 16:2989–98.
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Lukyanov AN. (2003). Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today 8:259–66.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. (2015). Global cancer statistics, 2012. CA Cancer J Clin 65:87–108.
   PubMed Web of Science ®Google Scholar
• Vandermeulen GW, Klok HA. (2004). Peptide/protein hybrid materials: enhanced control of structure and improved performance through conjugation of biological and synthetic polymers. Macromol Biosci 4:383–98.
   PubMed Web of Science ®Google Scholar
• Wang J, Sun Y, Liu Y, et al. (2005). Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi 8:283–90.
   PubMedGoogle Scholar
• Witting M, Obst K, Friess W, et al. (2015). Recent advances in topical delivery of proteins and peptides mediated by soft matter nanocarriers. Biotechnol Adv 33:1355–69.
   PubMed Web of Science ®Google Scholar
• Xu Y, Strickland EC, Fitzgerald MC. (2014). Thermodynamic analysis of protein folding and stability using a tryptophan modification protocol. Anal Chem 86:7041–8.
   PubMed Web of Science ®Google Scholar
• Yu ZW, Ju Y-H, Yang C-L, et al. (2015). Antitumor effect of recombinant human endostatin combined with cisplatin on rats with transplanted Lewis lung cancer. Asian Pac J Trop Med 8:664–7.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Zang Q, Jiang Z-M, et al. (2015). Clinical application of recombinant human endostatin in postoperative early complementary therapy on patients with non-small cell lung cancer in Chinese Mainland. Asian Pac J Cancer Prev 16:4013–18.
   PubMedGoogle Scholar